Cargando…

Disparate Effects of Diabetes and Hyperlipidemia on Experimental Kidney Disease

It is well established that diabetes is the major cause of chronic kidney disease worldwide. Both hyperglycemia, and more recently, advanced glycation endproducts, have been shown to play critical roles in the development of kidney disease. Moreover, the renin-angiotensin system along with growth fa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watson, Anna M. D., Gould, Eleanor A. M., Moody, Sarah C., Sivakumaran, Priyadharshini, Sourris, Karly C., Chow, Bryna S. M., Koïtka-Weber, Audrey, Allen, Terri J., Jandeleit-Dahm, Karin A. M., Cooper, Mark E., Calkin, Anna C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Physiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283908/ https://www.ncbi.nlm.nih.gov/pubmed/32581831 http://dx.doi.org/10.3389/fphys.2020.00518

Ejemplares similares

Endothelial reactive oxygen-forming NADPH oxidase 5 is a possible player in diabetic aortic aneurysm but not atherosclerosis
por: Ho, Florence, et al.
Publicado: (2022)

Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes
por: Soro-Paavonen, Aino, et al.
Publicado: (2008)

Diabetes and Hypertension Differentially Affect Renal Catecholamines and Renal Reactive Oxygen Species
por: Watson, Anna M. D., et al.
Publicado: (2019)

The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
por: Thomas, M. C., et al.
Publicado: (2012)

Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes
por: Charlton, Amelia, et al.
Publicado: (2020)

miR-200a Prevents Renal Fibrogenesis Through Repression of TGF-β2 Expression
por: Wang, Bo, et al.
Publicado: (2011)

Therapy of Canine Hyperlipidemia with Bezafibrate
por: De Marco, V., et al.
Publicado: (2017)

Comment on: Sukumar et al. Nox2 NADPH Oxidase Has a Critical Role in Insulin Resistance–Related Endothelial Cell Dysfunction. Diabetes 2013;62:2130–2134
por: Jandeleit-Dahm, Karin A.M., et al.
Publicado: (2013)

Cell-specific epigenetic changes in atherosclerosis
por: Khan, Abdul Waheed, et al.
Publicado: (2021)

Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
por: Hanssen, Nordin MJ, et al.
Publicado: (2019)

E-Cadherin Expression Is Regulated by miR-192/215 by a Mechanism That Is Independent of the Profibrotic Effects of Transforming Growth Factor-β
por: Wang, Bo, et al.
Publicado: (2010)

Alagebrium Reduces Glomerular Fibrogenesis and Inflammation Beyond Preventing RAGE Activation in Diabetic Apolipoprotein E Knockout Mice
por: Watson, Anna M.D., et al.
Publicado: (2012)

Sodium‐Glucose Co‐Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes‐Induced Atherosclerotic Plaque Instability
por: Chen, Yung‐Chih, et al.
Publicado: (2021)

Evaluating the efficacy and safety of GKT137831 in adults with type 1 diabetes and persistently elevated urinary albumin excretion: a statistical analysis plan
por: De Livera, Alysha M., et al.
Publicado: (2020)

Diabetes Alters Activation and Repression of Pro- and Anti-Inflammatory Signaling Pathways in the Vasculature
por: Di Marco, Elyse, et al.
Publicado: (2013)

Efficacy of Berberine Alone and in Combination for the Treatment of Hyperlipidemia: A Systematic Review
por: Koppen, Laura M., et al.
Publicado: (2017)

Advances in the Renin-Angiotensin-Aldosterone System: Relevance to Diabetic Nephropathy
por: Koitka, Audrey, et al.
Publicado: (2008)

Monogenic hyperlipidemias
por: Krasi, Geraldo, et al.
Publicado: (2019)

Hyperlipidemias and Obesity
por: Thiriet, Marc
Publicado: (2019)

PPAR Agonists and Cardiovascular Disease in Diabetes
por: Calkin, Anna C., et al.
Publicado: (2008)

Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo
por: Ballinger, Mandy L, et al.
Publicado: (2010)

c-Jun NH(2)-Terminal Kinase Activity in Subcutaneous Adipose Tissue but Not Nuclear Factor-κB Activity in Peripheral Blood Mononuclear Cells Is an Independent Determinant of Insulin Resistance in Healthy Individuals
por: Sourris, Karly C., et al.
Publicado: (2009)

Pre‐clinical evidence of a dual NADPH oxidase 1/4 inhibitor (setanaxib) in liver, kidney and lung fibrosis
por: Thannickal, Victor J., et al.
Publicado: (2023)

Pharmacological treatment of hypertension and hyperlipidemia in Izhevsk, Russia
por: Cybulsky, Marta, et al.
Publicado: (2016)

The Effect of Hyperlipidemia on the Course of Diabetic Retinopathy—Literature Review
por: Bryl, Anna, et al.
Publicado: (2022)

Morphological Changes of Parotid Gland in Experimental Hyperlipidemia
por: Daskala, Ioanna D., et al.
Publicado: (2011)

Hyperlipidemia and lipedematous scalp
por: Bukhari, Iqbal, et al.
Publicado: (2004)

Monascus purpureus Went rice in nephrotic hyperlipidemia
por: Gheith, O., et al.
Publicado: (2008)

Macrophage Polarization in Obesity and Type 2 Diabetes: Weighing Down Our Understanding of Macrophage Function?
por: Kraakman, Michael James, et al.
Publicado: (2014)

Primary hyperlipidemias : an atlas of investigation and diagnosis /
por: Davignon, J.
Publicado: (2009)

Globally elevating the AGE clearance receptor, OST48, does not protect against the development of diabetic kidney disease, despite improving insulin secretion
por: Zhuang, Aowen, et al.
Publicado: (2019)

Prevalence, treatment, and control of severe hyperlipidemia
por: Gold, Matthew E., et al.
Publicado: (2020)

Indications for apheresis as an ultima ratio treatment of refractory hyperlipidemias
por: Grützmacher, P., et al.
Publicado: (2015)

Association between obesity and hyperlipidemia among children.
por: Lai, S. W., et al.
Publicado: (2001)

Mycophenolate mofetil–induced hyperlipidemia with cutaneous manifestations
por: Yim, Rebecca M., et al.
Publicado: (2023)

Modulation of the Cellular Expression of Circulating Advanced Glycation End-Product Receptors in Type 2 Diabetic Nephropathy
por: Sourris, Karly C., et al.
Publicado: (2010)

Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease
por: Østergaard, Jakob A., et al.
Publicado: (2022)

Adipose-Derived Extracellular Vesicles: Systemic Messengers and Metabolic Regulators in Health and Disease
por: Bond, Simon T., et al.
Publicado: (2022)

Barriers and facilitators for screening and treatment of hyperlipidemia among patients with inflammatory arthritis
por: Navarro-Millán, Iris, et al.
Publicado: (2020)

Injury to the tunica media initiates atherogenesis in the presence of hyperlipidemia
por: Belhoul-Fakir, Hanane, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fnnj1n2qhto69kufsf8ouuglfi